Zoetis
Inc. (NYSE:ZTS) today announced that its Board of Directors has
appointed Paul M. Bisaro, Executive Chairman of Actavis plc, to the
company’s Board of Directors. Mr. Bisaro’s term will begin immediately
following the company’s 2015 Annual Meeting of Shareholders, which is
scheduled for May 1, 2015. With the addition of Mr. Bisaro, the Zoetis
Board will expand to 11 directors, and he will serve on the Compensation
Committee.
“We are pleased to announce that Paul will join the Zoetis Board,” said
Zoetis Chief Executive Officer Juan Ramón Alaix. “He brings extensive
business leadership and global healthcare experience to Zoetis, along
with a deep understanding of the pharmaceutical industry. He will be a
valuable addition to our board as we continue to grow our position as
the world’s leading animal health company.”
Mr. Bisaro has more than 20 years of experience in the healthcare
industry. He is Executive Chairman of Actavis plc, a global
pharmaceutical company focused on developing, manufacturing and
commercializing innovative branded pharmaceuticals, high-quality generic
and over-the-counter medicines, and biologic products.
He previously served as President, CEO and Chairman of the Board of
Actavis. Prior to joining Actavis (then Watson Pharmaceuticals), he was
President and Chief Operating Officer of Barr Pharmaceuticals, Inc. He
also served as General Counsel at Barr and held various additional
roles, including Senior Vice President of Strategic Business
Development. Prior to joining Barr, Mr. Bisaro was associated with the
law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell
and Reynolds. He also served as a Senior Consultant with Arthur Andersen
& Co.
About Zoetis
Zoetis (zô-EH-tis) is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on more than 60
years of experience in animal health, Zoetis discovers, develops,
manufactures and markets veterinary vaccines and medicines, complemented
by diagnostic products and genetic tests and supported by a range of
services. In 2014, the company generated annual revenue of $4.8 billion.
With approximately 10,000 employees worldwide at the beginning of 2015,
Zoetis serves veterinarians, livestock producers and people who raise
and care for farm and companion animals with sales of its products in
120 countries. For more information, visit www.zoetis.com.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains
forward-looking statements, which reflect the current views of Zoetis
with respect to business plans or prospects, future operating or
financial performance, expectations regarding products, future use of
cash and dividend payments, and other future events. These statements
are not guarantees of future performance or actions. Forward-looking
statements are subject to risks and uncertainties. If one or more of
these risks or uncertainties materialize, or if management's underlying
assumptions prove to be incorrect, actual results may differ materially
from those contemplated by a forward-looking statement. Forward-looking
statements speak only as of the date on which they are made. Zoetis
expressly disclaims any obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise. A further list and description of
risks, uncertainties and other matters can be found in our Annual Report
on Form 10-K for the fiscal year ended December 31, 2014, including in
the sections thereof captioned “Forward-Looking Information and Factors
That May Affect Future Results” and “Item 1A. Risk Factors,” in our
Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K.
These filings and subsequent filings are available online at www.sec.gov,
www.zoetis.com,
or on request from Zoetis.
Copyright Business Wire 2015